revascularization

ULTIMATE III: Use of IVUS for Coronary De Novo Lesion Drug Coated Balloon Angioplasty

Percutaneous coronary intervention (PCI) with drug eluting stents (DES) can present limitations, especially in the form of stent thrombosis or instent restenosis (ISR). These findings have furthered the development of drub coated balloons (DCB). The safety and efficacy of DCB have already been shown in the context of ISR and de novo small vessel coronary<a href="https://solaci.org/en/2024/07/12/ultimate-iii-use-of-ivus-for-coronary-de-novo-lesion-drug-coated-balloon-angioplasty/" title="Read more" >...</a>

ATC guiada por iFR ¿es igual en la DA que en el resto de los vasos?

Predictors of DCB Failure in De Novo Lesions

Percutaneous coronary intervention (PCI) with drug coated balloons (DCB) is a viable alternative, especially in patients at high risk of bleeding, side-branch lesions in coronary bifurcation, or in small coronary segments. De novo heart disease treated with DCB has been shown non-inferior to conventional DES stenting, according to the PICCOLETO-II trial.&nbsp; However, these interventions are<a href="https://solaci.org/en/2024/07/08/predictors-of-dcb-failure-in-de-novo-lesions-2/" title="Read more" >...</a>

Doctor con tabletas de aspirinas

Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk

Timely percutaneous intervention of STEMI patients effectively reduces MI size and mortality, which currently makes it the first line of treatment. A fundamental aspect is activation and platelet aggregation, which is why, in addition to creating networks to optimize STEMI treatment, prehospital drug treatments have been implemented.&nbsp; The COMPARECrush looked at whether early and powerful<a href="https://solaci.org/en/2024/07/08/prehospital-crushed-vs-integral-prasugrel-in-stemi-patients-with-large-myocardial-area-at-risk/" title="Read more" >...</a>

Resultados a 2 años del balón farmacológico Lutonix sobre la femoral superficial

Biolimus vs Paclitaxel Coated Balloons for the Treatment of In-Stent Restenosis

Drug eluting stent (DES) in-stent restenosis (ISR) is currently a challenging, seeing as it often requires repeat revascularization. The use of drug coated balloons (DCB) offers the advantage of delivering the drug without the need for re-stenting. This highlights the importance of the technological development of DCB, with diverse drug formulations and coating technologies. As<a href="https://solaci.org/en/2024/07/02/biolimus-vs-paclitaxel-coated-balloons-for-the-treatment-of-in-stent-restenosis/" title="Read more" >...</a>

Non-ST-Segment Elevation Myocardial Infarction in Elderly Patients

The world population is aging, and cardiovascular diseases are the leading cause of death in Western countries.&nbsp; It is increasingly common to find patients aged 70 or older with non-ST-segment elevation acute myocardial infarction (NSTEMI). However, this group has been excluded from most studies, and there is not enough information to determine whether a conservative<a href="https://solaci.org/en/2024/07/01/non-st-segment-elevation-myocardial-infarction-in-elderly-patients/" title="Read more" >...</a>

QFR Analysis of Coronary Lesions with TAVR

While transcatheter aortic valve replacement (TAVR) has shown benefits, significant coronary artery disease affects 50% or more of patients who undergo such procedure. However, it is still unclear which is the best treatment strategy or how to handle this condition. Quantitative flow ratio (QFR) could be a non-invasive option to assess the severity of coronary<a href="https://solaci.org/en/2024/06/29/qfr-analysis-of-coronary-lesions-with-tavr/" title="Read more" >...</a>

Events in CAD Patients Who Refused or Were Ineligible for CABG

When deciding on the optimal coronary artery revascularization treatment of coronary artery disease (CAD) patients, physicians normally assessed clinical presentation, surgical risk, survival expectation, and the likelihood of a better quality of life. Decisions are made after careful consideration, by the Heart Team, who will ponder options such as coronary artery bypass graft (CABG), percutaneous<a href="https://solaci.org/en/2024/06/26/events-in-cad-patients-who-refused-or-were-ineligible-for-cabg/" title="Read more" >...</a>

La estrategia invasiva en pacientes frágiles es segura

Complex PCI in Octogenarian

The octogenarian population has already reached 137 million and continues to grow. It is estimated to triple by 2050.&nbsp; This increase represents a big challenge, seeing as these patients are often more fragile, present more complex coronary artery disease and multiple comorbidities. This generally requires two or more procedures and more experience both from operators<a href="https://solaci.org/en/2024/06/18/complex-pci-in-octogenarian/" title="Read more" >...</a>

Cilostazol en pacientes diabéticos con revascularización periférica endovascular: Un paso más allá de la mejoría sintomática

Glycemic Control and Coronary Stent Failure

Diabetic patients have twice as high a risk of developing coronary artery disease (CAD). Additionally, CAD increases mortality risk. Patients with a history of percutaneous coronary intervention (PCI) tend to need repeat revascularization, even with second generation stents. To date, there are few studies assessing the role of glycemic control in stent failure, stent thrombosis,<a href="https://solaci.org/en/2024/06/13/glycemic-control-and-coronary-stent-failure/" title="Read more" >...</a>

Sirolimus-Eluting Balloon in Femoropopliteal Disease

Drug-eluting balloons (DEB) with paclitaxel have shown efficacy and safety in the treatment of femoropopliteal disease. Sirolimus-eluting balloons (DEB S) are currently being introduced. This new drug acts during the cellular resting phase (G0) and is considered potentially more effective than paclitaxel, which is a cytostatic drug. However, there is no conclusive evidence in this<a href="https://solaci.org/en/2024/06/13/sirolimus-eluting-balloon-in-femoropopliteal-disease/" title="Read more" >...</a>

Top